文献速递呼吸危重症与机械通气

急性呼吸窘迫综合征的最大肺复张开放肺通气策略(PHARLAP):一项II期多中心随机对照试验

Maximal Recruitment Open Lung Ventilation in Acute Respiratory Distress Syndrome (PHARLAP). A Phase II, Multicenter Randomized Controlled Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01

PHARLAP是一项II期多中心随机对照试验,纳入中重度ARDS成人患者,比较最大肺复张联合PEEP滴定及进一步限制潮气量策略与对照保护性通气。因ART试验发表而提前终止,实际随机115例(计划340例)。结果显示最大肺复张未减少28天无呼吸机天数或死亡率,但降低低氧辅助治疗新用率并增加新发心律失常。

要点

  • 最大肺复张策略未改善28天无呼吸机天数或死亡率。
  • 干预组新发心律失常发生率更高,需警惕心血管不良事件。
  • 干预组低氧辅助治疗(如吸入NO、ECMO、俯卧位)新用率更低。

核心结论

  • 与对照保护性通气相比,最大肺复张未减少无呼吸机天数或死亡率,与心血管不良事件增加相关,但低氧辅助治疗使用更少。

研究设计与样本

  • II期多中心随机对照试验,纳入中重度ARDS成人患者,因ART试验发表提前终止,实际随机115例(计划340例;57%男性;平均年龄53.6岁)。

主要发现

  • 28天无呼吸机天数:最大肺复张组中位16天(IQR 0-21,n=57) vs 对照组14.5天(IQR 0-21.5,n=56),P=0.95。
  • 死亡率:最大肺复张组24.6%(14/56) vs 对照组26.8%(15/56),P=0.79。
  • 气压伤发生率:最大肺复张组5.2%(3/57) vs 对照组10.7%(6/56),P=0.32。
  • 新发低氧辅助治疗(吸入NO、ECMO、俯卧位)使用:最大肺复张组较基线中位变化0(IQR 0-1) vs 对照组1(IQR 0-1),P=0.004。
  • 新发心律失常:最大肺复张组17例(29%) vs 对照组7例(13%),P=0.03。

临床怎么用

  • 对中重度ARDS患者,最大肺复张策略不应常规用于改善无呼吸机天数或死亡率。
  • 采用最大肺复张策略时需密切监测新发心律失常等心血管不良事件。

局限性

  • 研究因ART试验发表提前终止,实际样本量(115例)远低于计划样本量(340例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Open lung ventilation strategies have been recommended in patients with acute respiratory distress syndrome (ARDS).Objectives: To determine whether a maximal lung recruitment strategy reduces ventilator-free days in patients with ARDS.Methods: A phase II, multicenter randomized controlled trial in adults with moderate to severe ARDS. Patients received maximal lung recruitment, titrated positive end expiratory pressure and further Vt limitation, or control "protective" ventilation.Measurements and Main Results: The primary outcome was ventilator-free days at Day 28. Secondary outcomes included mortality, barotrauma, new use of hypoxemic adjuvant therapies, and ICU and hospital stay. Enrollment halted October 2, 2017, after publication of ART (Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial), when 115 of a planned 340 patients had been randomized (57% male; mean age, 53.6 yr). At 28 days after randomization, there was no difference between the maximal lung recruitment and control ventilation strategies in ventilator-free days (median, 16 d [interquartile range (IQR), 0-21 d], n = 57, vs. 14.5 d [IQR, 0-21.5 d], n = 56; P = 0.95), mortality (24.6% [n = 14/56] vs. 26.8% [n = 15/56]; P = 0.79), or the rate of barotrauma (5.2% [n = 3/57] vs. 10.7% [n = 6/56]; P = 0.32). However, the intervention group showed reduced use of new hypoxemic adjuvant therapies (i.e., inhaled nitric oxide, extracorporeal membrane oxygenation, prone; median change from baseline 0 [IQR, 0-1] vs. 1 [IQR, 0-1]; P = 0.004) and increased rates of new cardiac arrhythmia (n = 17 [29%] vs. n = 7 [13%]; P = 0.03).Conclusions: Compared with control ventilation, maximal lung recruitment did not reduce the duration of ventilation-free days or mortality and was associated with increased cardiovascular adverse events but lower use of hypoxemic adjuvant therapies.Clinical trial registered with www.clinicaltrials.gov (NCT01667146).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Hodgson CL, Cooper DJ, Arabi Y, et al. Maximal Recruitment Open Lung Ventilation in Acute Respiratory Distress Syndrome (PHARLAP). A Phase II, Multicenter Randomized Controlled Clinical Trial. Am J Respir Crit Care Med. 2019. PMID: 31356105. doi:10.1164/rccm.201901-0109OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。